Hyperthermic Intraperitoneal Chemotherapy With Cytoreductive Surgery Prolongs OS in Gastric Cancer

Share this content:
Investigators evaluated data from 277 patients with gastric cancer, 180 of whom underwent CRS plus HIPEC vs 97 who underwent CRS only.
Investigators evaluated data from 277 patients with gastric cancer, 180 of whom underwent CRS plus HIPEC vs 97 who underwent CRS only.
The following article features coverage from the 2018 Gastrointestinal Cancers Symposium. Click here to read more of Cancer Therapy Advisor's conference coverage.

Compared with cytoreductive surgery alone (CRSa), hyperthermic intraperitoneal chemotherapy (HIPEC) plus CRS prolongs overall survival (OS) among patients with gastric cancer and peritoneal carcinomatosis (PC), according to an abstract being presented at the 2018 Gastrointestinal Cancers Symposium in San Francisco, California.1

Investigators evaluated data from 277 patients with gastric cancer, 180 of whom underwent CRS plus HIPEC vs 97 who underwent CRSa. A Cox proportional hazards regression model with inverse probability of treatment weighting (IPTW), multivariate, and sensitivity analyses was used. PC extension was measured using the Peritoneal Cancer Index (PCI).

The 2 treatment arms had similar results, though PCI remained elevated among patients in the HIPEC plus CRS arm compared with the CRSa arm (median, 6 vs 2, respectively [P = .003]).

Patients treated with HIPEC plus CRS, however, had a prolonged OS of 18.2 months vs 12.1 months among CRSa patients.

Three- and 5- year OS rates of 26.21% and 19.87% vs 10.82% and 6.43% were noted for patients treated with HIPEC vs CRSa, respectively (hazard ratio [HR], 1.66; 95% CI, 1.17-2.37; P = .005). Three- and 5-year disease-free survival rates was also improved in the HIPEC arm (20.40% and 17.05% vs 5.87% and 3.76%, respectively; P = .001).

No significant differences for mortality rate, grade 3 to 4 morbidity, and surgical morbidity were observed.

The authors concluded that “this treatment, when optimal CRS can be achieved, should be considered as the gold standard since outcomes remain grim with chemotherapies.”

Read more of Cancer Therapy Advisor's coverage of the 2018 Gastrointestinal Cancers Symposium by visiting the conference page.

Reference

  1. Bonnot PE, Piessen G, Pocard M, et al. CYTO-CHIP: cytoreductive surgery versus cytoreductive surgery and hyperthermic intraperitoneal chemotherapy for gastric cancer with peritoneal metastasis: a propensity-score analysis from BIG RENAPE and FREGAT working groups. Oral presentation at: 2018 Gastrointestinal Cancers Symposium; January 18-20, 2018; San Francisco, CA.

Related Resources

You must be a registered member of Cancer Therapy Advisor to post a comment.

Sign Up for Free e-newsletters

Regimen and Drug Listings

GET FULL LISTINGS OF TREATMENT Regimens and Drug INFORMATION

Bone Cancer Regimens Drugs
Brain Cancer Regimens Drugs
Breast Cancer Regimens Drugs
Endocrine Cancer Regimens Drugs
Gastrointestinal Cancer Regimens Drugs
Gynecologic Cancer Regimens Drugs
Head and Neck Cancer Regimens Drugs
Hematologic Cancer Regimens Drugs
Lung Cancer Regimens Drugs
Other Cancers Regimens
Prostate Cancer Regimens Drugs
Rare Cancers Regimens
Renal Cell Carcinoma Regimens Drugs
Skin Cancer Regimens Drugs
Urologic Cancers Regimens Drugs